← Trials/Trial dossier/NCT03720548

CompletedPhase 1

A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)

A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Healthy Subjects and Patients With Alzheimer's Disease

Lead sponsor

Eli Lilly and Company

Asset

Remternetug

Listed sites

Recruiting sites

Enrollment

actual

Study population

Alzheimer’s disease

Key I/E criteria

•mild-to-moderate AD•Amyloid biomarker required (PET)•MRI contraindications excluded•History of intracranial hemorrhage excluded

Primary endpoint

•Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID17019

Secondary IDJ1G-MC-LAKAEli Lilly and Company

NCT IDNCT03720548

Timeline

Milestones

Study first posted2018-10-25actual

Study start2018-11-05actual

Primary completion2019-05-14actual

Study completion2019-05-14actual

Last update posted2019-06-05actual

Assets

Drug assets

Remternetug

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age18 Years

Maximum age85 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

Part A:

•Overtly healthy males or females as determined by medical history and physical examination

•Are between 18 to 45 years old, inclusive

•Male participants agree to use a reliable method of birth control during the study and 3 months following the last dose of the investigational product

•Female participants not of child-bearing potential

•Have a body mass index of 18.0 to 32 kilograms per square meter (kg/m²) inclusive

Part B:

•Present with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild-to-moderate AD

•Positive florbetapir scan

•Men or nonfertile women, at least 55 years of age. Nonfertile is defined as hysterectomy and/or bilateral oophorectomy, or amenorrhea for at least 1 year

•Have up to 2 study partners who can provide health information related to the study about the participant. Study partner(s) will provide a separate written informed consent to participate

Exclusion criteria

•Have significant abnormalities in brain magnetic resonance imaging (MRI); or have contraindications for MRI

•Have significant allergic reactions to LY3372993, or related compounds, or have significant allergies to humanized monoclonal antibodies, diphenhydramine, epinephrine, or methylprednisolone

•Have clinically significant neurological or psychological illness, or other illnesses that could affect the study results

Part A:

•Have family history of early onset Alzheimer's Disease (AD)

•Have impaired cognitive function

Part B:

•History of intracranial hemorrhage, cerebrovascular aneurysm or arteriovenous malformation, or carotid artery occlusion, or stroke or epilepsy

•Previously dosed in any other study investigating active immunization against amyloid beta (Aβ)

•Previously dosed in any other study investigating passive immunization against Aβ within the last 6 months

•Have current serious or unstable illnesses

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Amyloid biomarkers

1 endpoint

Secondary/protocol endpoint

Pharmacodynamics (PD): Change from Baseline in Amyloid Load

Time frame:Baseline, Week 28

change from baseline, improvement

Safety / tolerability / PK

5 endpoints

Primary/protocol endpoint

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Time frame:Baseline up to Day 562

event count, event

Secondary/protocol endpoint

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of LY3372993 After a Single Dose

Time frame:Predose up to Day 85

concentration, descriptive

Secondary/protocol endpoint

PK: Maximum Observed Concentration (Cmax) of LY3372993 After a Single Dose

Time frame:Predose up to Day 85

concentration, descriptive

Secondary/protocol endpoint

PK: AUC of LY3372993 at Steady State after Multiple Doses

Time frame:Week 14 through Week 18

concentration, descriptive

Secondary/protocol endpoint

PK: Cmax of LY3372993 at Steady State After Multiple Doses

Time frame:Week 14 through Week 18

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.